Lextro Bio Solutions

Executive Summary

Lextro Bio Solutions Pvt. Ltd. is a Hyderabad-based contract research organization (CRO) that provides integrated drug discovery and development services. Founded in 2018, the company leverages recombinant protein production, antibody generation, high-throughput in vitro screening, and AAALAC-accredited preclinical models to support programs in oncology, infectious disease, autoimmune, and metabolic disorders. Its platform enables customers to accelerate target validation and lead optimization for both small-molecule and biologic therapeutics. As a private preclinical-stage CRO with 50-200 employees, Lextro focuses on cost-effective, end-to-end solutions for pharmaceutical and biotech clients. Despite limited public financial disclosures, the company’s AAALAC accreditation and broad therapeutic coverage position it as a capable partner for early-stage drug development. The absence of disclosed funding or valuation suggests a conservative growth trajectory, but its service-based model provides steady revenue streams. With the biotech outsourcing market expanding, Lextro is well-placed to capture demand for preclinical services, particularly in oncology and infectious disease. Future success hinges on securing major client contracts and expanding its service portfolio to include advanced modalities.

Upcoming Catalysts (preview)

• Q3 2026New preclinical facility expansion or certification (e.g., OECD GLP)60% success
• Q4 2026Major partnership or service agreement with a top-20 pharma company40% success
• H1 2027Launch of an AI-driven drug discovery or high-throughput screening platform50% success